Literature DB >> 23324827

Genetic and pathologic evolution of early secondary gliosarcoma.

Kari-Elise T Codispoti1, Stacy Mosier, Robert Ramsey, Ming-Tseh Lin, Fausto J Rodriguez.   

Abstract

Gliosarcoma is a subset of glioblastoma with glial and mesenchymal components. True secondary gliosarcomas (i.e. progressing from lower-grade precursors) in the absence of radiation therapy are very rare. We report the unique case of a 61-year-old male who developed a fibrillary astrocytoma (WHO grade II). In the absence of adjuvant therapy the tumor recurred 3 years later as a gliosarcoma comprising an infiltrating glial component and a curious, early high-grade sarcomatous component surrounding intratumoral vessels. DNA was extracted from formalin fixed paraffin-embedded tissues from the precursor low-grade glioma and from the glioma and sarcomatous components at progression. Samples were hybridized separately to a 300 k Illumina SNP array. IDH1(R132H) mutant protein immunohistochemistry was positive in all tissue components. Alterations identified in all samples included dup(1)(q21q41), del(1)(q41qter), del(2)(q31.1), del(2)(q36.3qter), del(4)(q35.1qter), dup(7)(q22.2q36.3), del(7)(q36.3qter), del(9)(p21.3pter), dup(10)(p13pter), del(10)(q26.13q26.3), dup(17) (q12qter), and copy neutral LOH(20)(p11.23p11.21). The recurrent tumor had additional alterations, including del(3)(p21.31q13.31), del(18)(q21.2qter), and a homozygous del(9)(p21.3)(CDKN2A locus) and the sarcoma component had, in addition, del(4)(p14pter), del(6)(q12qter), del(11)(q24.3qter), and del(16)(p11.2pter). In conclusion, unique copy number alterations were identified during tumor progression from a low-grade glioma to gliosarcoma. A subset of alterations developed specifically in the sarcomatous component.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23324827      PMCID: PMC3991122          DOI: 10.1007/s10014-012-0132-y

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  32 in total

1.  The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.

Authors:  A H Banham; N Beasley; E Campo; P L Fernandez; C Fidler; K Gatter; M Jones; D Y Mason; J E Prime; P Trougouboff; K Wood; J L Cordell
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

2.  Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.

Authors:  Inês Crespo; Ana Luísa Vital; Ana Belen Nieto; Olinda Rebelo; Hermínio Tão; Maria Celeste Lopes; Catarina Resende Oliveira; Pim J French; Alberto Orfao; María Dolores Tabernero
Journal:  J Mol Diagn       Date:  2011-08-30       Impact factor: 5.568

3.  Genomic changes in gliomas detected using single nucleotide polymorphism array in formalin-fixed, paraffin-embedded tissue: superior results compared with microsatellite analysis.

Authors:  Shuko Harada; Lindsay B Henderson; James R Eshleman; Christopher D Gocke; Peter Burger; Constance A Griffin; Denise A S Batista
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

Review 4.  The tumor suppressor RASSF1A in human carcinogenesis: an update.

Authors:  R Dammann; U Schagdarsurengin; C Seidel; M Strunnikova; M Rastetter; K Baier; G P Pfeifer
Journal:  Histol Histopathol       Date:  2005-04       Impact factor: 2.303

Review 5.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

6.  Changes of AXIN-1 and beta-catenin in neuroepithelial brain tumors.

Authors:  Tamara Nikuseva Martić; Nives Pećina-Slaus; Vesna Kusec; Tomislav Kokotović; Hana Musinović; Davor Tomas; Martina Zeljko
Journal:  Pathol Oncol Res       Date:  2009-07-25       Impact factor: 3.201

7.  Hypermethylation of the RASSF1A gene in gliomas.

Authors:  Yunxia Gao; Ming Guan; Bing Su; Weiwei Liu; Min Xu; Yuan Lu
Journal:  Clin Chim Acta       Date:  2004-11       Impact factor: 3.786

8.  Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas.

Authors:  Luke Hesson; Ivan Bièche; Dietmar Krex; Emmanuelle Criniere; Khê Hoang-Xuan; Eamonn R Maher; Farida Latif
Journal:  Oncogene       Date:  2004-03-25       Impact factor: 9.867

9.  PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma.

Authors:  J R Molina; N K Agarwal; F C Morales; Y Hayashi; K D Aldape; G Cote; M-M Georgescu
Journal:  Oncogene       Date:  2011-08-01       Impact factor: 9.867

Review 10.  Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity.

Authors:  Seunggu J Han; Isaac Yang; Tarik Tihan; Michael D Prados; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-07-18       Impact factor: 4.130

View more
  2 in total

1.  Hypermutated phenotype in gliosarcoma of the spinal cord.

Authors:  Christopher S Hong; Gregory A Kuzmik; Adam J Kundishora; Aladine A Elsamadicy; Andrew B Koo; Declan McGuone; Nicholas A Blondin; Michael L DiLuna; E Zeynep Erson-Omay
Journal:  NPJ Precis Oncol       Date:  2021-02-12

2.  Molecular and clonal evolution in recurrent metastatic gliosarcoma.

Authors:  Kevin J Anderson; Aaron C Tan; Jonathon Parkinson; Michael Back; Marina Kastelan; Allison Newey; Janice Brewer; Helen Wheeler; Amanda L Hudson; Samirkumar B Amin; Kevin C Johnson; Floris P Barthel; Roel G W Verhaak; Mustafa Khasraw
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-02-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.